The stock of Verve Therapeutics Inc (NASDAQ: VERV) has increased by 76.00 when compared to last closing price of 6.27.Despite this, the company has seen a gain of 72.83% in its stock price over the last five trading days. businesswire.com reported 2025-06-17 that NEW YORK–(BUSINESS WIRE)–Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verve Therapeutics, Inc. (NASDAQ: VERV) to Eli Lilly and Company is fair to Verve shareholders. Under the terms of the proposed transaction, Verve shareholders will receive $10.50 per share in cash, plus one non-tradeable contingent value right per share entitling the holder to receive up to an additional $3.00 per share upon the achievement of certain milestones. Halper Sadeh encourag.
Is It Worth Investing in Verve Therapeutics Inc (NASDAQ: VERV) Right Now?
The 36-month beta value for VERV is at 1.72. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for VERV is 65.76M, and currently, shorts hold a 30.18% of that float. The average trading volume for VERV on June 17, 2025 was 3.47M shares.
VERV’s Market Performance
VERV’s stock has seen a 72.83% increase for the week, with a 138.34% rise in the past month and a 91.25% gain in the past quarter. The volatility ratio for the week is 1.84%, and the volatility levels for the past 30 days are at 5.02% for Verve Therapeutics Inc The simple moving average for the past 20 days is 99.42% for VERV’s stock, with a 92.37% simple moving average for the past 200 days.
Analysts’ Opinion of VERV
H.C. Wainwright, on the other hand, stated in their research note that they expect to see VERV reach a price target of $15. The rating they have provided for VERV stocks is “Buy” according to the report published on April 08th, 2024.
Canaccord Genuity gave a rating of “Buy” to VERV, setting the target price at $29 in the report published on April 13th of the previous year.
VERV Trading at 122.42% from the 50-Day Moving Average
After a stumble in the market that brought VERV to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 18.59% of gains for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VERV starting from Kathiresan Sekar, who sale 9,822 shares at the price of $4.15 back on Apr 02 ’25. After this action, Kathiresan Sekar now owns 346,686 shares of Verve Therapeutics Inc, valued at $40,761 using the latest closing price.
Nickerson Joan, the Chief Administrative Officer of Verve Therapeutics Inc, sale 2,777 shares at $4.15 during a trade that took place back on Apr 02 ’25, which means that Nickerson Joan is holding 17,420 shares at $11,525 based on the most recent closing price.
Stock Fundamentals for VERV
Current profitability levels for the company are sitting at:
- -3.5 for the present operating margin
- 0.36 for the gross margin
The net margin for Verve Therapeutics Inc stands at -3.04. The total capital return value is set at -0.37. Equity return is now at value -34.26, with -26.89 for asset returns.
Based on Verve Therapeutics Inc (VERV), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -2.08.
Currently, EBITDA for the company is -221.91 million with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of 16.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.84.
Conclusion
In conclusion, Verve Therapeutics Inc (VERV) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
